Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

Key facts

Sponsor

SystImmune Inc.

Principal Investigator

Loren VanPelt

SystImmune Inc.

Intervention

BL-M11D1(drug)

Enrollment

120 target

Eligibility

18 years · All sexes

Timeline

2024 – 2027

Study locations (14)

• City of Hope, Duarte, California, United States
• UCLA Ronald Reagan Medical Center, Los Angeles, California, United States
• Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States
• Moffitt Cancer Center, Tampa, Florida, United States
• START Midwest/The Cancer and Hematology Center, Grand Rapids, Michigan, United States
• Oncology Hematology Care Clinical Trials, LLC, Cincinnati, Ohio, United States
• The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
• WVCI Oncology Associates of Oregon, Eugene, Oregon, United States
• SCRI -TriStar BMT, Nashville, Tennessee, United States
• MD Anderson Cancer Center, Houston, Texas, United States
• Texas Oncology, P.A., San Antonio, Texas, United States
• Virginia Cancer Specialists, Fairfax, Virginia, United States
• Oncology & Hematology Associates of Southwest Virginia, Inc., Roanoke, Virginia, United States
• Fred Hutchinson Cancer Center, Seattle, Washington, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Inherited acute myeloid leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06782542
  Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
  Justin Watts, MD
• RECRUITINGPHASE2NCT06557421
  De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients
  Institut Paoli-Calmettes
• RECRUITINGPHASE1NCT07130695
  Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation
  Virginia Commonwealth University
• RECRUITINGPHASE1NCT07320235
  Imetelstat Combinations in Relapsed AML
  Douglas Tremblay
• RECRUITINGPHASE2NCT06904482
  Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
  Case Comprehensive Cancer Center
• RECRUITINGNCT07163728
  Leptin: A Marker for AML Chemo-Sensitivity
  Fujian Medical University Union Hospital
• RECRUITINGNANCT06697600
  A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
  University of Rochester
• RECRUITINGPHASE2, PHASE3NCT06972641
  Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation
  Ruijin Hospital

See all trials for Inherited acute myeloid leukemia →